Seeking Alpha

Arena Pharmaceuticals (ARNA -3.6%) continues to give back some of the massive gains it enjoyed...

Arena Pharmaceuticals (ARNA -3.6%) continues to give back some of the massive gains it enjoyed after the FDA approved its weight-loss drug Belviq. Orexigen, which surged on the news as well, is -4.7%. Vivus, though, (VVUS +1.5%) is still climbing ahead of an FDA decision on its Qnexa diet drug on July 17.
Comments (6)
  • VVUS will hit $37 after the announcement.
    2 Jul 2012, 01:45 PM Reply Like
  • yes i agree. VVUS will be in the $37-$40 range after approval.
    2 Jul 2012, 07:49 PM Reply Like
  • Don't you mean $3.70. I just don't see it getting approved. If it does it will be heavily restricted and I just don't see a need for it since we now have one approved (ARNA) which will be a blockbuster worldwide. Good luck though on your position Rodney.
    2 Jul 2012, 09:50 PM Reply Like
  • Little info from Ceo/WIVUS may help to take the right investor actions
    2 Jul 2012, 06:13 PM Reply Like
  • Arna to $20/shr
    2 Jul 2012, 07:24 PM Reply Like
  • It is true, VVUS will likely see another slash on their weight loss drug. And talk about the spike already being built into the current price... In my opinion VVUS is extremely overvalued. It's not long till this over heating stock plummets. with so many risk factors VVUS will likely be rejected and even if approved will have lot's of restrictions and post approval studies. either way I don't see this one moving anywhere but down. ARNA will got to about 15 per share pre FDA decision on QNEXA and if a rejection sticker is posted will jump to around 20 and cap off around 25. Happy hunting.
    2 Jul 2012, 10:09 PM Reply Like
DJIA (DIA) S&P 500 (SPY)